General Information of Drug (ID: DM5OWXA)

Drug Name
NBM-BMX Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM5OWXA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [3]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03808870) A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.